Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$14.61
$0.04(0.36%)
At close: 4:00 PM EDT
$14.61
$0.04(0.36%)
Day’s Range― - ―
52-Week Range$4.88 - $15.87
Previous CloseN/A
Volume1.35M
Average Volume (3M)2.91M
Market Cap
$1.54B
Enterprise Value$1.53B
Total Cash (Recent Filing)$433.30M
Total Debt (Recent Filing)$54.63M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Oct 29, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.57
Shares Outstanding138,476,820
10 Day Avg. Volume2,741,975
30 Day Avg. Volume2,913,618
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$24.91Price Target Upside70.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Phase III Efficacy And DurabilityPositive Phase III results with rapid onset and six-month durability strengthen the probability that COMP360 can deliver meaningful clinical value. Durable efficacy may support regulatory approval, physician adoption, differentiation from alternatives, and a more defensible commercial position over time.
Cash Runway And Low LeverageA substantial cash balance and minimal debt provide financial flexibility while the company completes regulatory work and prepares for launch. This runway reduces near-term refinancing pressure and supports continued clinical development, although it does not eliminate the need to reach sustainable revenue.
Established Launch InfrastructureExisting treatment-site infrastructure and strong reported prescriber interest could shorten the path from approval to patient access. Using established interventional psychiatry settings may reduce adoption friction and give COMPASS a practical foundation for scaling a monitored therapy.
Bears Say
Pre-revenue Model With Escalating LossesCOMPASS remains dependent on external capital because it has no reported revenue and its losses and cash burn are increasing. Until commercialization begins and reimbursement develops, ongoing spending on trials, regulatory work, and launch preparation will continue to pressure financial sustainability.
Regulatory And Launch Timing UncertaintyEven with positive clinical data, patient access and launch timing depend on federal and state rescheduling as well as final REMS requirements. Delays could defer revenue, extend cash consumption, and complicate coordination among treatment sites, prescribers, and patients.
Reimbursement Strategy Remains UnsettledPositive payer feedback has not yet translated into finalized coverage or reimbursement arrangements. Uncertain formulary access and potential early payment friction could slow prescribing, constrain realized demand, and make the initial commercial ramp less predictable than clinical results alone imply.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $4.88 and its highest was $15.87 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $1.54B.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Aug 05, 2026. The company reported -$1.88 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$1.492.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.36.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 138,476,820 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$1.88 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went up 15.085%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.91 (70.49% Upside)
$24.91 (70.49% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 96%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.39%
12-Months-Change
Fundamentals
Return on Equity
-398.21%
Trailing 12-Months
Asset Growth
71.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
COMPASS Pathways
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPS Company Deck
CMPS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$24.91
▲(70.49% Upside)
Technical Analysis
Ownership Overview
0.39% Insiders
1.25% Mutual Funds
0.37% Other Institutional Investors
88.87% Public Companies and Individual Investors